Sustiva

(efavirenz)

ApprovedSmall molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Efavirenz is used to treat HIV infection by helping to stop the virus from multiplying in the body, and is typically taken as part of a combination therapy with other HIV medications.[2] Sustiva is currently approved and in use across 17 indications[4].[1]

Sustiva is one of 387 small molecule programs targeting Lipodystrophy. It is currently in Approved.

Indications

204

Total Trials

Active Trials

386

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

LipodystrophyActive, not recruiting

Oxidative StressActive, not recruiting

Hepatitis BActive, not recruiting

Prostate CancerApproved

Non-Hodgkins LymphomaApproved

Viral DiseaseActive, not recruiting

Immunodeficiency DiseaseActive, not recruiting

AIDSApproved

FibrosisActive, not recruiting

AnxietyActive, not recruiting

LipodystrophyApproved

Active, not recruiting

Oxidative StressApproved

Active, not recruiting

Hepatitis BApproved

Active, not recruiting

Prostate CancerApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Viral DiseaseApproved

Active, not recruiting

Immunodeficiency DiseaseApproved

Active, not recruiting

AIDSApproved

Approved

FibrosisPreclinical

Active, not recruiting

AnxietyPreclinical

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 2

Lexiscan

Astellas

Preclinical

1 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Rilvegostomig

1 8

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 9

Bisphosphonate

Amgen

Preclinical

2 10

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Breast Cancer

NCT05076682

Q4 2028

N/ARecruiting

T Cell

NCT06823596

Clinical

Trials by Indication[1]

Effectiveness19 trials

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00005918·730 enrolled

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

Completed· Gilead logo

Gilead·Phase 2·NCT00002419·25 enrolled

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Completed·IInternational Medical Center of Japan·Phase 3·NCT00280969·71 enrolled

Show 16 more trials

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Completed· GSK logo

GSK·Phase 2·NCT00002213·80 enrolled

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002387·80 enrolled

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00016718·43 enrolled

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

Completed· GSK logo

GSK·Phase 4·NCT00005018·150 enrolled

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

Completed· GSK logo

GSK·Phase 4·NCT00004585·40 enrolled

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Completed· Gilead logo

Gilead·Phase 2·NCT00002234·25 enrolled

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00004852

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001087·300 enrolled

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Completed·AAbbott·Phase 2·NCT00038220·40 enrolled

A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000939·150 enrolled

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000922·1,710 enrolled

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00050895·775 enrolled

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002235·6 enrolled

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Unknown status· GSK logo

GSK·Phase 4·NCT00011895·400 enrolled

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Unknown status· GSK logo

GSK·Phase 4·NCT00005017·300 enrolled

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000914·800 enrolled

Treatment12 trials

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100594·100 enrolled

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 4·NCT00442962·54 enrolled

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000885·440 enrolled

Show 9 more trials

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158405·840 enrolled

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT01541085·33 enrolled

Treatment Options for Protease Inhibitor-exposed Children

Completed·—·Phase 3·NCT01146873·300 enrolled

Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients

Completed·PPeking Union Medical College Hospital·N/A·NCT04596488·25 enrolled

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100568·44 enrolled

Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00120510·816 enrolled

Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities

Completed·CCIPRA SA·N/A·NCT00255840·812 enrolled

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000903·444 enrolled

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status·AAgouron Pharmaceuticals·Phase 4·NCT00005000·200 enrolled

HIV infection10 trials

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Completed·SSEARCH Research Foundation·Phase 1/2·NCT02475915·15 enrolled

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006154·165 enrolled

Show 7 more trials

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Completed·KKirby Institute·Phase 4·NCT00192660·80 enrolled

Efficacy of Efavirenz 400mg vs. 600mg Combined With Lamivudine and Tenofovir in Treatment Naive HIV Infection

Unknown status·PPeking Union Medical College Hospital·N/A·NCT04463784·500 enrolled

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01040091·34 enrolled

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00102960·377 enrolled

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

No longer available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT00162188

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

No longer available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT00162227

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00013520·1,125 enrolled

Drug10 trials

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Suspended·TTriangle Pharmaceuticals·Phase 3·NCT00002362

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00014937·240 enrolled

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00017758·56 enrolled

Show 7 more trials

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00074581·3,526 enrolled

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002227·60 enrolled

A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Unknown status·TTriangle Pharmaceuticals·Phase 3·NCT00006208

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Completed·GGermans Trias i Pujol Hospital·Phase 1·NCT00307502·675 enrolled

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

Completed· GSK logo

GSK·Phase 3·NCT00053638·345 enrolled

A Study to Compare Two Anti-HIV Drug Combinations

Completed· Roche logo

Roche·Phase 3·NCT00002447·146 enrolled

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000912·475 enrolled

Interaction9 trials

GSK1349572 Drug Interaction Study With Efavirenz

Completed· GSK logo

GSK·Phase 1·NCT01098526·12 enrolled

A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01588002·40 enrolled

Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00960570·30 enrolled

Show 6 more trials

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz

Completed· Novartis logo

Novartis·Phase 1·NCT05330273·14 enrolled

Drug-Drug Interaction Potential of Mavorixafor

Completed·XX4 Pharmaceuticals·Phase 1·NCT06914869·38 enrolled

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT05995249·172 enrolled

Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04680091·20 enrolled

TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01241773·48 enrolled

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT01472380·30 enrolled

71 more indications

Tuberculosis6 trials

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01571414·52 enrolled

Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00802802·67 enrolled

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Completed·AANRS, Emerging Infectious Diseases·Phase 2·NCT00822315·155 enrolled

Show 3 more trials

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 4·NCT01380080·851 enrolled

Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen

Unknown status·NNational Center for Research Resources (NCRR)·N/A·NCT00018083

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00115609·70 enrolled

Tics6 trials

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

Completed·KKirby Institute·Phase 3·NCT01271894·40 enrolled

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT04459598·32 enrolled

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Unknown status·SSt Stephens Aids Trust·Phase 1·NCT02832778·35 enrolled

Show 3 more trials

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

Completed·UUniversity of Nebraska··NCT01886404·30 enrolled

TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz

Completed·CCenters for Disease Control and Prevention·Phase 2·NCT00023413·20 enrolled

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

Terminated·JJohns Hopkins University·Phase 4·NCT01980342·1 enrolled

HIV5 trials

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002220·120 enrolled

Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients

Unknown status·MMahidol University·Phase 1·NCT02421289·190 enrolled

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001086·300 enrolled

Show 2 more trials

Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin

Completed·BBamrasnaradura Infectious Diseases Institute·Phase 3·NCT00483054·142 enrolled

ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

Completed·VViRx·Phase 2·NCT00004582

Immunodeficiency5 trials

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01632345·342 enrolled

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01516970·312 enrolled

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Completed· GSK logo

GSK·Phase 2·NCT01641809·244 enrolled

Show 2 more trials

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00350272·76 enrolled

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00110305·368 enrolled

Pregnancy4 trials

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00042289·1,578 enrolled

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

Completed·WWestat·Phase 4·NCT01618305·408 enrolled

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

Completed·SSt Stephens Aids Trust·Phase 1·NCT02499874·26 enrolled

Show 1 more trial

A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation

Completed·AAdeniyi Olagunju··NCT02269462·460 enrolled

Children4 trials

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000893·103 enrolled

PK TDF in Thai HIV-infected Children

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·N/A·NCT02404259·32 enrolled

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00234091·300 enrolled

Show 1 more trial

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00260078·75 enrolled

Tenofovir Disoproxil Fumarate3 trials

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00118898·1,864 enrolled

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01709084·426 enrolled

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Completed· Gilead logo

Gilead·Phase 3·NCT00112047·517 enrolled

ART3 trials

Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

Completed·AAbbott·Phase 2·NCT00038532·24 enrolled

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06797674·34 enrolled

A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)

Completed·GGöteborg University·Phase 4·NCT01445223·242 enrolled

Efficacy and Safety3 trials

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

Completed·AANRS, Emerging Infectious Diseases·Phase 3·NCT02777229·616 enrolled

Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg

Terminated·OOswaldo Cruz Foundation·Phase 4·NCT00533390·130 enrolled

Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB

Completed·—·Phase 3·NCT01805258·135 enrolled

Clinical Trial3 trials

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00903682·157 enrolled

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 3·NCT00543725·680 enrolled

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 3·NCT00540449·694 enrolled

Malaria3 trials

HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

Completed·UUniversity of California, San Francisco·Phase 3·NCT00978068·176 enrolled

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

Completed·FFran Aweeka·Phase 1·NCT00697892·38 enrolled

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

Completed·UUniversity of California, San Francisco·Phase 3·NCT00993031·389 enrolled

Immune2 trials

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

Completed·UUniversity of California, Davis·N/A·NCT00661960·25 enrolled

Increasing HAART-Induced Immune Restoration With Cyclosporine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00031070·40 enrolled

Drug Interactions2 trials

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00005762·90 enrolled

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

Completed·IIndiana University·Phase 4·NCT02401256·70 enrolled

HIV-12 trials

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Completed· GSK logo

GSK·Phase 2·NCT00951015·208 enrolled

A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·Phase 2·NCT00476424·28 enrolled

Tenofovir2 trials

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02945163·184 enrolled

Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158457·40 enrolled

HCV Coinfection2 trials

Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

Completed·JJuan Macías·Phase 4·NCT01900015·45 enrolled

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

Completed·UUniversity of Hawaii·Phase 4·NCT01147107·80 enrolled

Efficacy2 trials

Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy

Completed·VViriom·Phase 2/3·NCT02489461·150 enrolled

Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients

Unknown status·SShanghai Public Health Clinical Center·Phase 3·NCT04513379·80 enrolled

Immune System2 trials

A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002448·40 enrolled

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled

Lipodystrophy2 trials

Mechanisms of Lipodystrophy in HIV-Infected Pateints

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00457665·56 enrolled

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00006190

Advanced2 trials

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Terminated·RRush University Medical Center·Phase 4·NCT00775606·15 enrolled

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 4·NCT00342355·1,771 enrolled

Hepatitis C2 trials

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Completed·UUniversity of Cincinnati·Phase 1·NCT00545558·18 enrolled

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100581·2 enrolled

Adult2 trials

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Completed· Roche logo

Roche·Phase 2·NCT00002239·68 enrolled

Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00196612·350 enrolled

Antiretroviral Treatment2 trials

Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00122538·52 enrolled

Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily

Completed·GGermans Trias i Pujol Hospital·Phase 3·NCT00314626·99 enrolled

Pilot Study2 trials

Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00196599·39 enrolled

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection

Completed·UUniversity of Alabama at Birmingham·N/A·NCT00734344·18 enrolled

Trial2 trials

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05560360·20 enrolled

Cryptococcal Optimal ART Timing Trial

Completed·UUniversity of Minnesota·Phase 4·NCT01075152·177 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

Completed·KKirby Institute·Phase 3·NCT01011413·636 enrolled

A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients

Completed·NNorthwestern University·Phase 3·NCT00002230·100 enrolled

Concentration2 trials

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02226991·34 enrolled

Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT00299091·31 enrolled

Liver2 trials

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

Completed·IIndiana University·N/A·NCT01104376·61 enrolled

Strategies for Delivering Anti-HIV Therapy in South Africa

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00080522·813 enrolled

Women2 trials

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

Completed·UUniversity of Nebraska·Phase 2·NCT02722421·28 enrolled

Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana

Completed·—··NCT03336346·148 enrolled

HIV-1 infection2 trials

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01489046·297 enrolled

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01254656·108 enrolled

Single Dose2 trials

A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants

Not yet recruiting· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 1·NCT07341672·80 enrolled

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

Completed· Pfizer logo

Pfizer·Phase 1·NCT03762928·12 enrolled

Side Effects2 trials

Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV

Completed·RRadboud University Medical Center··NCT03227653·144 enrolled

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00021463·342 enrolled

Hepatitis B2 trials

Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00051090

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Completed·IInternational Antiviral Therapy Evaluation Center·Phase 4·NCT00127959·24 enrolled

Toxicity1 trial

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

Completed·SSt Stephens Aids Trust·Phase 3·NCT00792324·24 enrolled

Plasmodium Falciparum1 trial

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 1/2·NCT01632891·52 enrolled

Type 2 Diabetes1 trial

Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes

Terminated·UUniversity of Southern Denmark·Phase 1·NCT04504045·10 enrolled

Central Nervous System1 trial

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

Completed·KKirby Institute·Phase 3·NCT01451333·32 enrolled

Intensive Care1 trial

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00028327·250 enrolled

LAM1 trial

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00013897

Progesterone1 trial

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00016601·76 enrolled

Female1 trial

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

Completed·TTibotec, Inc·Phase 1·NCT01268839·20 enrolled

Completed·WWashington University School of Medicine·Phase 1/2·NCT01668147·13 enrolled

Moringa Oleifera1 trial

Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

Completed·UUniversity of Zimbabwe··NCT01410058·19 enrolled

TED1 trial

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

Completed·GGeorgetown University·Phase 3·NCT00727597·101 enrolled

Lymphoma1 trial

Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

Completed·IInstitut Bergonié·Phase 1·NCT01878890·25 enrolled

Amorphous Solid Dispersions1 trial

Bioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid Dispersions

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT03886766·16 enrolled

Gastrointestinal1 trial

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

Completed·UUniversity of California, Davis·Phase 4·NCT00870363·44 enrolled

Pancreatic Cancer1 trial

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Completed·IInstitut Bergonié·Phase 2·NCT00964171·19 enrolled

T Cell1 trial

The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY

Recruiting·UUniversity of Toronto·N/A·NCT06823596·26 enrolled

Adverse Events1 trial

Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage

Completed·SSociedad Andaluza de Enfermedades Infecciosas·Phase 4·NCT00556634·114 enrolled

Anxiety1 trial

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz

Completed·UUniversity Hospital, Geneva·N/A·NCT00792584·50 enrolled

SMA1 trial

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06698016·16 enrolled

Breast Cancer1 trial

Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05076682·80 enrolled

Metastatic Prostate Cancer1 trial

Efavirenz in Treating Patients With Metastatic Prostate Cancer

Completed·IInstitut Bergonié·Phase 2·NCT00964002·61 enrolled

Statin1 trial

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Completed·NNYU Langone Health·Phase 1·NCT01695954·34 enrolled

Adult Subject1 trial

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03983239·32 enrolled

Treatment Failure1 trial

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled

Infection1 trial

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

Unknown status·PPENTA Foundation·Phase 2/3·NCT01641016·160 enrolled

Fibrosis1 trial

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00023218

Medication1 trial

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001122·74 enrolled

HIV-Infected Individuals1 trial

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Terminated·UUniversity of California, San Diego·N/A·NCT01293123·2 enrolled

Oxidative Stress1 trial

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

Completed·IIndiana University·Phase 4·NCT01585038·40 enrolled

Combination Therapy1 trial

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

Completed·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT01989910·107 enrolled

Itching1 trial

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

Terminated·TThe Cleveland Clinic·Phase 4·NCT01194856·1 enrolled

Imaging1 trial

LAAM-HAART PET Imaging

Completed·WWashington University School of Medicine·Phase 1·NCT01935830·10 enrolled

Caffeine1 trial

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT05067439·26 enrolled

Genetic Polymorphism1 trial

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

Completed·IIndiana University·N/A·NCT00668395·73 enrolled

Unspecified14 trials

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

Completed·UUniversity of Nebraska·Phase 2·NCT01789879·60 enrolled

Combination of Efavirenz and Truvada - COMET Study

Completed· Gilead logo

Gilead·Phase 4·NCT00224458·400 enrolled

A Study of Indinavir Taken With or Without DMP 266

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002393·300 enrolled

Show 11 more trials

Optimization of Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02935075·184 enrolled

A Study of Efavirenz in Combination With Stavudine and Didanosine

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002225·60 enrolled

Risk of CV Events With EFV vs. EFV-free Regimens

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02426866·29,612 enrolled

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)

Terminated· GSK logo

GSK·Phase 2·NCT01231555·23 enrolled

Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00992069·37 enrolled

An Open-label DDI Study of Omaveloxolone in Healthy Subjects

Completed· Biogen logo

Biogen·Phase 1·NCT05909644·20 enrolled

Sustiva Levels With Use of a Gel Capsule

Completed·UUniversity of Minnesota·Phase 4·NCT01087814·16 enrolled

The Neurocognitive Sub-study of Encore1

Completed·KKirby Institute·Phase 3·NCT01516060·71 enrolled

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT04390334·24 enrolled

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02164812·58 enrolled

Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158470·100 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 17, 1998

SUSTIVA

NDA NDA020972

Feb 1, 2002

SUSTIVA

NDA NDA021360

Sources

References

[1]
ClinicalTrials.gov — 204 trial records for efavirenz. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Sustiva drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — efavirenz compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for efavirenz. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021360). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Sustiva

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Trials by Indication[1]

Effectiveness19 trials

Treatment12 trials

HIV infection10 trials

Drug10 trials

Interaction9 trials

Tuberculosis6 trials

Tics6 trials

HIV5 trials

Immunodeficiency5 trials

Pregnancy4 trials

Children4 trials

Tenofovir Disoproxil Fumarate3 trials

ART3 trials

Efficacy and Safety3 trials

Clinical Trial3 trials

Malaria3 trials

Immune2 trials

Drug Interactions2 trials

HIV-12 trials

Tenofovir2 trials

HCV Coinfection2 trials

Efficacy2 trials

Immune System2 trials

Lipodystrophy2 trials

Advanced2 trials

Hepatitis C2 trials

Adult2 trials

Antiretroviral Treatment2 trials

Pilot Study2 trials

Trial2 trials

Safety and Efficacy2 trials

Concentration2 trials

Liver2 trials

Women2 trials

HIV-1 infection2 trials

Single Dose2 trials

Side Effects2 trials

Hepatitis B2 trials

Toxicity1 trial

Plasmodium Falciparum1 trial

Type 2 Diabetes1 trial

Central Nervous System1 trial

Intensive Care1 trial

LAM1 trial

Progesterone1 trial

Female1 trial

MPR1 trial

Prospective1 trial

Long-term Follow-up1 trial

AIN1 trial

Moringa Oleifera1 trial

TED1 trial

Lymphoma1 trial

Amorphous Solid Dispersions1 trial

Gastrointestinal1 trial

Pancreatic Cancer1 trial

T Cell1 trial

Adverse Events1 trial

Anxiety1 trial

SMA1 trial

Breast Cancer1 trial

Metastatic Prostate Cancer1 trial

Statin1 trial

Adult Subject1 trial

Treatment Failure1 trial

Infection1 trial

Fibrosis1 trial

Medication1 trial

HIV-Infected Individuals1 trial

Oxidative Stress1 trial

Combination Therapy1 trial

Itching1 trial

Imaging1 trial